🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥IFCT-2103 DIAL: Analysis of the Phase 2 Part of a Phase 2-3 Randomized Trial, Comparing Continuation Pembrolizumab (± Pemetrexed) up to 2 Years Versus Observation (± Pemetrexed), in Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Disease Control (DC) at 6 Months 🎙️Dr. Anne-Claire Toffart 🔢2618RO 🎯Similar 18-Mo OS With De-escalation (Observation) vs Continuation: 88.1% vs 83.3% (n=84) 🎯Lower irAEs With De-escalation (47.8% vs 85.1%) 🎯Phase 3 Accrual Ongoing ☑️NCT05255302 🔗 https://t.co/p4tFUd6NwV @OncoAlert @Larvol @myESMO @IASLC